This is a multicenter, one-arm, prospective, observational study，intended to assess evaluation of efficacy and safety of Apremilast in Chinese patients with moderate-to-severe plaque psoriasis。During this study, it is expected to collect data at at baseline and weeks 2, 6, 10, 16, and 20 after treatment。

Inclusion Criteria:

• Males or females, ≥ 18 years of age at the time of signing the informed consent document；
• Patients with moderate-to-severe plaque psoriasis：Simultaneously meet (1)and (2): (1)PASI≥ 3；(2) DLQI ≥ 6；
• Subject is a candidate for phototherapy and/or systemic therapy
• Patients who wish to be treated with Apremilast and sign the informed consent

Exclusion Criteria:

• Allergy to Apremilast or any component of the study drug；
• Use of phototherapy within 4 weeks prior to randomization；Use of systemic drugs or biologic agents within 4 half-life periods prior to randomization；Patients with inadequate response or intolerance to previous systemic therapy do not need to consider drug washout；
• Currently using potent cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin, etc.)；
• History of substance abuse, suicide attempts, or mental illness；
• Patients who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period；
• Pustular type, erythroderma type and other psoriasis patients；
• Other circumstances that investigators don't consider appropriate to include.

Chinese patients with moderate to severe plaque psoriasis